352 related articles for article (PubMed ID: 19302594)
1. Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels.
Terai K; Nara H; Takakura K; Mizukami K; Sanagi M; Fukushima S; Fujimori A; Itoh H; Okada M
Br J Pharmacol; 2009 Apr; 156(8):1267-78. PubMed ID: 19302594
[TBL] [Abstract][Full Text] [Related]
2. Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia.
De Schutter TM; Behets GJ; Geryl H; Peter ME; Steppan S; Gundlach K; Passlick-Deetjen J; D'Haese PC; Neven E
Kidney Int; 2013 Jun; 83(6):1109-17. PubMed ID: 23486515
[TBL] [Abstract][Full Text] [Related]
3. [Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease].
Nagano N; Miyata S; Abe M; Wakita S; Kobayashi N; Wada M
Clin Calcium; 2005 Sep; 15 Suppl 1():35-9; discussion 39-40. PubMed ID: 16272627
[TBL] [Abstract][Full Text] [Related]
4. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.
Cozzolino M; Staniforth ME; Liapis H; Finch J; Burke SK; Dusso AS; Slatopolsky E
Kidney Int; 2003 Nov; 64(5):1653-61. PubMed ID: 14531797
[TBL] [Abstract][Full Text] [Related]
5. Slowing the progression of vascular calcification in hemodialysis.
Chertow GM
J Am Soc Nephrol; 2003 Sep; 14(9 Suppl 4):S310-4. PubMed ID: 12939387
[TBL] [Abstract][Full Text] [Related]
6. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.
Henley C; Colloton M; Cattley RC; Shatzen E; Towler DA; Lacey D; Martin D
Nephrol Dial Transplant; 2005 Jul; 20(7):1370-7. PubMed ID: 15855208
[TBL] [Abstract][Full Text] [Related]
7. Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia.
Tamagaki K; Yuan Q; Ohkawa H; Imazeki I; Moriguchi Y; Imai N; Sasaki S; Takeda K; Fukagawa M
Nephrol Dial Transplant; 2006 Mar; 21(3):651-9. PubMed ID: 16311258
[TBL] [Abstract][Full Text] [Related]
8. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats.
Cozzolino M; Dusso AS; Liapis H; Finch J; Lu Y; Burke SK; Slatopolsky E
J Am Soc Nephrol; 2002 Sep; 13(9):2299-308. PubMed ID: 12191974
[TBL] [Abstract][Full Text] [Related]
9. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats.
Katsumata K; Kusano K; Hirata M; Tsunemi K; Nagano N; Burke SK; Fukushima N
Kidney Int; 2003 Aug; 64(2):441-50. PubMed ID: 12846739
[TBL] [Abstract][Full Text] [Related]
10. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
11. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis.
Takei T; Otsubo S; Uchida K; Matsugami K; Mimuro T; Kabaya T; Akiba T; Nitta K
Nephron Clin Pract; 2008; 108(4):c278-83. PubMed ID: 18434749
[TBL] [Abstract][Full Text] [Related]
12. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?
Oliveira RB; Cancela AL; Graciolli FG; Dos Reis LM; Draibe SA; Cuppari L; Carvalho AB; Jorgetti V; Canziani ME; Moysés RM
Clin J Am Soc Nephrol; 2010 Feb; 5(2):286-91. PubMed ID: 19965540
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
Koizumi M; Fukagawa M
Clin Calcium; 2010 Nov; 20(11):1700-8. PubMed ID: 21037391
[TBL] [Abstract][Full Text] [Related]
14. Phosphate restriction significantly reduces mortality in uremic rats with established vascular calcification.
Finch JL; Lee DH; Liapis H; Ritter C; Zhang S; Suarez E; Ferder L; Slatopolsky E
Kidney Int; 2013 Dec; 84(6):1145-53. PubMed ID: 24107846
[TBL] [Abstract][Full Text] [Related]
15. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial.
Toussaint ND; Lau KK; Polkinghorne KR; Kerr PG
Nephrology (Carlton); 2011 Mar; 16(3):290-8. PubMed ID: 21342323
[TBL] [Abstract][Full Text] [Related]
16. Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients.
Nolan CR; Qunibi WY
Curr Opin Nephrol Hypertens; 2003 Jul; 12(4):373-9. PubMed ID: 12815333
[TBL] [Abstract][Full Text] [Related]
17. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
18. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
19. Use of sevelamer to examine the role of intraluminal phosphate in the pathogenesis of secondary hyperparathyroidism.
Phelps KR; Stote KS; Mason D
Clin Nephrol; 2014 Sep; 82(3):191-201. PubMed ID: 25079864
[TBL] [Abstract][Full Text] [Related]
20. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
